Literature DB >> 11464934

Versailles minimal dataset for diagnosis of ALS: a distillate of the 2nd Consensus Conference on accelerating the diagnosis of ALS. Versailles 2nd Consensus Conference participants.

B R Brooks1.   

Abstract

The 2nd Consensus Conference (Versailles) recommended that an ALS knowledge-base for initial healthcare providers, diagnosing neurologists and confirming neurologists should be defined to include a simplified version of diagnostic criteria less formal than the World Federation of Neurology El Escorial Revisted Criteria ('ALS diagnosis - An algorithm'), a set of rules concerning red flags which should increase the suspicion of ALS as the diagnosis and minimize the time between suspicion and referral for confirmation of diagnosis ('ALS axioms of referral'), as well as a site of symptom onset-specific checklist of minimal clinical examination, neuroimaging, electrodiagnostic, pulmonary function and laboratory test information required to confirm the diagnosis of ALS ('Versailles minimal dataset'). Although introductory discussions addressed the advantages and disadvantages of earlier diagnosis, false-positive or false-negative diagnosis, the frequency of follow-up and what potential biological markers to be followed, these issues will have to be further evaluated at future consensus conferences.

Entities:  

Mesh:

Year:  2000        PMID: 11464934     DOI: 10.1080/14660820050515629

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  6 in total

1.  Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis.

Authors:  Angela Rosenbohm; Gabriele Nagel; Raphael S Peter; Torben Brehme; Wolfgang Koenig; Luc Dupuis; Dietrich Rothenbacher; Albert C Ludolph
Journal:  JAMA Neurol       Date:  2018-05-01       Impact factor: 18.302

2.  Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia.

Authors:  Raphael Simon Peter; Angela Rosenbohm; Luc Dupuis; Torben Brehme; Jan Kassubek; Dietrich Rothenbacher; Gabriele Nagel; Albert Christian Ludolph
Journal:  Eur J Epidemiol       Date:  2017-10-03       Impact factor: 8.082

3.  Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS)--registry Swabia.

Authors:  Gabriele Nagel; Hatice Unal; Angela Rosenbohm; Albert C Ludolph; Dietrich Rothenbacher
Journal:  BMC Neurol       Date:  2013-02-17       Impact factor: 2.474

4.  Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis - results from a population- based ALS registry in Germany.

Authors:  Gabriele Nagel; Raphael S Peter; Angela Rosenbohm; Wolfgang Koenig; Luc Dupuis; Dietrich Rothenbacher; Albert C Ludolph
Journal:  Sci Rep       Date:  2017-06-29       Impact factor: 4.379

5.  Incidence and geographical variation of amyotrophic lateral sclerosis (ALS) in Southern Germany--completeness of the ALS registry Swabia.

Authors:  Hatice Uenal; Angela Rosenbohm; Johannes Kufeldt; Patrick Weydt; Katharina Goder; Albert Ludolph; Dietrich Rothenbacher; Gabriele Nagel
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

6.  Novel mutations support a role for Profilin 1 in the pathogenesis of ALS.

Authors:  Bradley N Smith; Caroline Vance; Emma L Scotter; Claire Troakes; Chun Hao Wong; Simon Topp; Satomi Maekawa; Andrew King; Jacqueline C Mitchell; Karan Lund; Ammar Al-Chalabi; Nicola Ticozzi; Vincenzo Silani; Peter Sapp; Robert H Brown; John E Landers; Safa Al-Sarraj; Christopher E Shaw
Journal:  Neurobiol Aging       Date:  2014-10-31       Impact factor: 5.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.